Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab
In this cohort study of eligible infants younger than 8 months, receipt of RSV immunization through maternal RSV vaccine or nirsevimab improved in the 2024-2025 compared with the 2023-2024 RSV seasons. However, infants with public insurance were less likely to receive either product, highlighting persistent disparities in RSV immunization warranting targeted interventions.
Authors
- Erika L. Abramson (ORCID: https://orcid.org/0000-0003-0474-7139)
- Anna P. Staniczenko
- Moeun Son (ORCID: https://orcid.org/0000-0002-3014-5222)
- Deborah A. Levine (ORCID: https://orcid.org/0000-0002-7951-8595)
- Jin-Young Han (ORCID: https://orcid.org/0000-0002-6500-3945)
- Kevin Strobino
- Laura E. Riley
- Jessica M. DeAngelis
Institutions
- Cornell University (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.59663
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jain Foundation
- Amgen
- Children's Hospital of Philadelphia
- Pediatric Epilepsy Research Foundation
- Harmony Biosciences
- Horizon Therapeutics
- Epilepsiatutkimussäätiö
- Weill Cornell Medical College